title: State of the art treatment of nasal polyposis.
abstract: BACKGROUND
  Nasal polyposis represents the end point of multiple inflammatory pathways and controversy continues as to the exact roles of medical and surgical approaches in the management of nasal polyposis.
  
  
  METHODS
  A combination of both is often required to manage polyps adequately with surgery and intranasal steroids remaining the mainstay of therapy.
  
  
  RESULTS
  Fortunately, new technological advances are making surgery safer and more efficient. In the postoperative period, debridement is effective in reducing the formation of adhesions, and topical medications may play a beneficial role in preventing polyp reformation.
  
  
  CONCLUSIONS
  Additional investigations into the optimal perioperative medical management is needed to ensure optimal surgical outcomes.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, University of California, Davis School of Medicine, Sacramento, USA.
authors.forename: Rony K
authors.initials: RK
authors.lastname: Aouad
authors.forename: Alexander G
authors.initials: AG
authors.lastname: Chiu
mesh_terms: D000818:Animals; D000888:Antibodies, Anti-Idiotypic / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D019819:Budesonide / Q000627:therapeutic use*; D003646:Debridement; D004724:Endoscopy; D006801:Humans; D007073:Immunoglobulin E / Q000276:immunology; D009298:Nasal Polyps / Q000188:drug therapy / Q000601:surgery / Q000628:therapy*; D000069444:Omalizumab; D010256:Paranasal Sinuses / Q000601:surgery; D015995:Prevalence; D012225:Rhinoplasty; D013256:Steroids / Q000627:therapeutic use
chemical_list: D000888:Antibodies, Anti-Idiotypic; D061067:Antibodies, Monoclonal, Humanized; D013256:Steroids; D000069444:Omalizumab; D007073:Immunoglobulin E; D019819:Budesonide